Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease

Conditions

• Diabete Type 2
• Non Alcoholic Fatty Liver

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• Aspirin — DRUG
  Participants received 100 mg of aspirin (aspirin protect®) as oral daily doses for 6 months.
• Dapagliflozin (10Mg Tab) along with standard medical therapy — DRUG
  Participants received 10 mg of dapagliflozin (Diaflozimet ®) as oral once-daily doses for 6 months.

Study Details

Non-alcoholic fatty liver disease (NAFLD) is a prevalent hepatic manifestation of metabolic syndrome, encompassing a spectrum of liver disorders from steatosis to non-alcoholic steatohepatitis (NASH), with potential progression to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Given the global health burden of NAFLD, therapeutic interventions targeting its pathophysiological mechanisms are crucial.

Key Dates

Start date

Apr 4, 2023

Status verified

Dec 2025

Primary completion

Apr 5, 2025

Completion

Sep 19, 2025

Study Design

Enrollment

80 participants (actual)

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Arms

• Experimental: aspirin group
  Participants were received 100 mg of aspirin as oral daily doses for 6 months.
• Experimental: Dapagliflozin group
  Participants were received 10 mg of dapagliflozin as oral once-daily doses for 6 months.

Primary Outcome Measure

lipid profile and Fibroscan results [ Time Frame: 6 months ]

Related Studies

• Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
  Recruiting · Pichamol Jirapinyo, MD, MPH · Boston, Massachusetts
• Combined Circulatory and Dietary Interventions for Neuropathy
  Not Yet Recruiting · Loma Linda University · Loma Linda, California